B-Cell Lymphoblastic Leukemia (B-ALL) monitoring, minimal residual disease (MRD) detection
B-Cell Lymphoblastic Leukemia (B-ALL) monitoring, minimal residual disease (MRD) detection-994
ALL-MRD
B-ALL MRD
B-cell ALL MRD
Aids in monitoring a previously confirmed diagnosis of B-cell lymphoblastic leukemia
Yellow ACD (A or B)
- Submission of bilateral specimens is not required
- Label specimen appropriately (bone marrow)
Include 5 to 10 unstained bone marrow aspirate smears, if possible.
Yellow ACD (A or B)
Bone marrow
Dk green Sodium heparin (Na hep), no gel
Whole blood:
Yellow ACD (A or B)
Lavender (EDTA), 4mL
Dk green Sodium heparin (Na hep), no gel
Immediately following collection, mix sample thoroughly by gentle inverting 8 - 10 times, to prevent clotting
- Send original collection tube, do not aliquot
- Label as blood
- If possible, include 5 to 10 unstained blood smears
Dk green Sodium heparin (Na hep), no gel
Lavender (EDTA), 4mL
Copy of flow cytometry report
Ambient - 72 hours
Specimen must be received at MCL within 72 hours
Immunophenotyping
This test will be processed as a laboratory consultation. An interpretation of the immunophenotypic findings and correlation with the morphologic features will be provided by a hematopathologist for every case.
This test is only appropriate for patients who have a previous confirmed diagnosis of B-cell lymphoblastic leukemia.
Treatment with antibodies to CD19 may interfere with the ability to detect minimal residual disease (MRD).
first cell surface, cytoplasmic or nuclear marker
88185 x 9 - Flow cytometry
additional cell surface, cytoplasmic or nuclear marker (each)
88188 - Flow Cytometry Interpretation, 9 to 15 Markers (if appropriate)